Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI351 plus platinum chemotherapy and bevacizumab in first-line KRAS G12C-mutant non-squamous NSCLC
ChiCTR2400090974Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Oct 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fulzerasib in non-small cell lung cancer (NSCLC), sponsored by Henan Cancer Hospital. Primary endpoints: Objective response rate, Adverse events and serious adverse events and 1 more. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
fulzerasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400090974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090974.